Insulin resistance and atherosclerosis

Insulin resistance characterizes type 2 diabetes and the metabolic syndrome, disorders associated with an increased risk of death due to macrovascular disease. In the past few decades, research from both the basic science and clinical arenas has enabled evidence-based use of therapeutic modalities s...

Full description

Saved in:
Bibliographic Details
Published inEndocrinology and metabolism clinics of North America Vol. 37; no. 3; p. 603
Main Authors Razani, Babak, Chakravarthy, Manu V, Semenkovich, Clay F
Format Journal Article
LanguageEnglish
Published United States 01.09.2008
Subjects
Animals
Atherosclerosis - etiology
Cardiovascular Diseases - prevention & control
Cholesterol, LDL - blood
Humans
Inflammation - physiopathology
Insulin Resistance
JNK Mitogen-Activated Protein Kinases - physiology
NF-kappa B - physiology
Reactive Oxygen Species - metabolism
Signal Transduction
Online AccessGet more information

Cover

More Information
Summary:Insulin resistance characterizes type 2 diabetes and the metabolic syndrome, disorders associated with an increased risk of death due to macrovascular disease. In the past few decades, research from both the basic science and clinical arenas has enabled evidence-based use of therapeutic modalities such as statins and angiotensin-converting enzyme inhibitors to reduce cardiovascular (CV) mortality in insulin-resistant patients. Recently, promising drugs such as the thiazolidinediones have come under scrutiny for possible deleterious CV effects. Ongoing research has broadened our understanding of the pathophysiology of atherosclerosis, implicating detrimental effects of inflammation and the cellular stress response on the vasculature. In this review, we address current thinking that is shaping our molecular understanding of insulin resistance and atherosclerosis.
ISSN:0889-8529
DOI:10.1016/j.ecl.2008.05.001